Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · lyophilized powder, vial

Epic Peptides Lab · USA

Document number: PL-SDS-053
Revision: 1.0 · 2026-10-03

Follistatin-344

lyophilized powder, vial

1Identification

Product Identifier

Follistatin-344

Document Number

PL-SDS-053

Catalogue Items Covered

Id
2194
Name
Follistatin 344 1mg
Sku
PL-FST344-1MG-VIAL

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification: Not classified as hazardous under OSHA HCS 2012 (29 CFR 1910.1200) or UN GHS, on the basis of the supplier safety data sheets consulted.
Label Elements: No data available.
Signal Word: No data available.
Other Hazards: No data available.

3Composition / information on ingredients

Description

Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap.

Composition

Name
Follistatin-344
Full
Recombinant human follistatin (FST-344 precursor isoform)
Cas
Not assigned
Conc
≥ 95% (dry basis, as supplied)
Qty
1 mg per vial

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.

5Fire-fighting measures

Fire Fighting Information: Combustible organic solid; finely divided powder may form dust clouds. Not flammable in the quantities supplied.

6Accidental release measures

Spill And Clean Up Procedures: Avoid dust formation. Dampen spilled powder with water, wipe up with absorbent material, place in a sealed container for disposal and clean the area with water and detergent.

7Handling and storage

Safe Handling: Open vials only in a clean area. Avoid generating or inhaling dust; weigh or reconstitute inside a ventilated enclosure when the full contents are handled as a dry powder. Reconstitute by adding diluent slowly to the vial wall; do not shake. Wash hands after handling.
Safe Storage: Store the sealed vial at the temperature stated in Section 9 (typically −20 °C for peptides, 2–8 °C for proteins), desiccated and protected from light. Allow the vial to reach room temperature before opening to avoid condensation. Reconstituted solutions: 2–8 °C, protected from light; use within the period established by your laboratory.
Storage Temperature: 2–8 °C (sealed vial); −20 °C for long-term storage; protected from light and moisture
Incompatible Materials: denaturants

8Exposure controls / personal protection

Occupational Exposure Limits: No data available.
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Solid

Appearance

White lyophilized powder

Properties

Odor: Characteristic (Cayman)
Ph: Not applicable (solid); aqueous solutions typically pH 4–7
Melting: Undetermined / not applicable (protein denatures)
Boiling: Not applicable
Flash: Not applicable (non-flammable solid); combustible organic material
Vapour: Negligible (solid)
Density: No data available (bulk density of lyophilized cake is low)
Solubility: Water: soluble (Cayman); reconstitute at 100 ug/mL in sterile PBS (R&D Systems)
Logp: Not applicable
Decomp: No data available; peptides decompose above about 200 °C
Other: Recombinant human follistatin; FST-344 precursor isoform ~38 kDa (predicted 34.7 kDa for aa 30-344, appears 39-56 kDa glycosylated, R&D Systems).

10Stability and reactivity

Stability And Reactivity

Reactivity: No dangerous reactions known (Cayman). Protein: sensitive to heat, proteases, repeated freeze-thaw and adsorption to surfaces.
Incompatible: Strong oxidizing agents, strong acids/bases, denaturants (generic protein SDS language).
Decomposition: No dangerous decomposition products known (Cayman); combustion: carbon oxides, nitrogen oxides.
Conditions To Avoid: Heat, repeated freeze-thaw cycles (R&D Systems), moisture; store lyophilized at -20 to -80 degC.

Conditions To Avoid

Heat, repeated freeze-thaw cycles (R&D Systems), moisture; store lyophilized at -20 to -80 degC

Incompatible Materials

denaturants

11Toxicological information

Toxicological Information: Acute toxicity, oral
No data available

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
No irritant effect (Cayman)

Serious eye damage/irritation
No irritating effect (Cayman)

Respiratory or skin sensitisation
No data in SDS; recombinant protein powders are potential respiratory sensitisers (H334 remark, see notes)

Germ cell mutagenicity
No data available

Carcinogenicity
None of the ingredients listed by IARC, NTP, OSHA-Ca (Cayman)

Reproductive toxicity
No data available. Pharmacological remark: follistatin binds activin/inhibin and myostatin; activin/inhibin signalling regulates FSH secretion and gonadal function (reproductive-endocrine activity) - remark only, not a GHS classification.

STOT, single exposure
No data available

STOT, repeated exposure
No data available

Aspiration hazard
No data available
Routes Of Exposure: Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: Cayman: water hazard class 1 (self-assessment), slightly hazardous for water. Protein - readily biodegradable; no ecotoxicity data.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Protein not listed on TSCA (biologic/peptide not on inventory); Cayman lists buffer salts NaCl, KH2PO4, KCl as TSCA ACTIVE. R&D exemption applies to research use.
Carcinogen Listings: Not listed by IARC, NTP, OSHA; not on California Prop 65.
Dea: Not a controlled substance.
Other: Not an approved drug (investigational; gene-therapy constructs in trials). WADA remark: follistatin is explicitly named on the WADA Prohibited List S4.4 (myostatin inhibitors - 'myostatin-binding proteins, e.g. follistatin') - prohibited at all times; note as remark only.

Carcinogen Listings

No data available.

16Other information

Revision: October 3, 2026
Sources Consulted: Cayman Chemical - Follistatin

R&D Systems / Bio-Techne - Recombinant Human Follistatin
Confidence: medium
Additional Information: Lyophilised recombinant or purified protein. Inhalation of protein dusts can sensitise susceptible individuals; avoid generating dust and handle the dry powder in a ventilated enclosure. Not classified for respiratory sensitisation because no substance-specific data exist.

WADA Prohibited List class S4.4.

Back to SDS list